However, a reliable reduction in opioid requirements took several weeks. associated with demyelination and degeneration [1]. The course of the disease is usually highly variable; however, pregnancy usually enhances the course of MS, especially during the last trimester [2]. There is evidence that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can trigger or cause numerous neurological disorders linked with the central and peripheral nervous systems. Possible mechanisms include BPH-715 cytokine-induced neuroinflammation, disruption of the blood-brain barrier, direct contamination of glial cells, and autoimmune responses. Central nervous system diseases include demyelinating diseases such as acute disseminated encephalomyelitis (ADEM), acute necrotizing encephalopathy (ANE), and MS [3]. We statement an unusual case of a young pregnant woman with a new diagnosis of outstanding highly active relapsing-remitting multiple sclerosis (RRMS) brought on by a SARS-CoV-2 contamination. Within 24 hours of the onset of neurological symptoms, the patient required intensive care unit (ICU) treatment and had to be intubated. Core symptoms included rapidly progressive spastic tetraparesis with eventually being tetraplegic, severe dyspnea, dysphagia, anarthria, bilateral visual impairment, and severe pain. We summarize the challenging and prolonged treatment of the patient due to the severity of the clinical presentation and the concurrent pregnancy, which ultimately resulted in a very positive end result with almost full recovery. This case statement could aid others who may be confronted with a similar situation. == Case presentation == Clinical findings The timeline of the clinical course is also illustrated in Physique1. Four days after the onset of an upper respiratory tract contamination, later confirmed as SARS-CoV-2 contamination, a 32-year-old previously healthy pregnant woman at 17+2 weeks gestation developed neurological symptoms including headaches, radiating neck pain, and a rapidly deteriorating spastic tetraparesis, which required admission to the emergency department. Symptoms worsened rapidly and drastically, and within just a few hours, the patient experienced tetraplegic with severe spasticity. The neurological examination revealed the following deficits: bilateral visual impairment (visual acuity < 0.2), dyspnea, anarthria, dysphagia, reduction in sensory functions, with a sensory truncal level advancing to C2 with severe hyperalgesia, increased BPH-715 reflexes of all extremities, spastic tetraplegia. Throughout the clinical course, cognitive function remained intact, enabling communication through vision closure and slight head nodding. Due to the clinical severity, the patient had to be directly transferred to the ICU with protective intubation on the same day. == Physique 1. Case statement timeline. Summary of clinical findings, diagnostic, and therapy. == PEG: percutaneous endoscopic gastrostomy, MRI: magnetic resonance imaging, ENMG: electromyography, GBS: Guillain-Barr syndrome, MS: multiple sclerosis, MOGAD: Myelin oligodendrocyte glycoprotein antibody-associated disease, NMOS: neuromyelitis optica spectrum, ADEM: acute disseminated encephalomyelitis. Diagnostic assessment The initial magnetic resonance imaging (MRI) of the brain and cervical spine revealed multiple demyelinating lesions with contrast enhancement in both the brain and spinal cord, as well as right-sided optic neuropathy (Physique2). These findings fulfilled the McDonald 2017 criteria for RRMS. Cerebrospinal fluid (CSF) analysis revealed a mildly elevated cell count (6 cells/l) without evidence of infectious agents and no indication of a blood-brain barrier disruption. However, positive oligoclonal bands Rabbit Polyclonal to p63 (OCBs) were detected, suggesting intrathecal immunoglobulin synthesis. Screening for anti-neuromyelitis optica (NMO) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in the serum in two reference laboratories (University or college Hospital of Zurich, University or college Hospital of Basel) with different assays was unfavorable. Electroneurography (ENMG) showed no evidence of Guillain-Barr syndrome. As shown in Table1, numerous BPH-715 additional laboratory tests revealed no evidence of any other rheumatological, autoimmune, or BPH-715 paraneoplastic diseases. Therefore, RRMS was finally diagnosed. == Table 1..